COI Pharmaceuticals

COI Pharmaceuticals is a biotechnology venture entity that offers operational support and infrastructure to biotech companies. Established in 2013, it operates as a Community of Innovation, providing a fully-equipped R&D facility and industry mentors to help entrepreneurial scientists succeed. By eliminating operational distractions, COI Pharmaceuticals enables scientists to focus on advancing their ideas in drug discovery.

The company collaborates with various partners to launch and support early-stage life science companies. Notably, in 2015, COI Pharmaceuticals expanded its collaboration with GlaxoSmithKline (GSK) to fund and launch additional companies through the development of clinical candidates. This collaboration has led to the formation of multiple companies, including Sitari Pharmaceuticals and Silarus Therapeutics, which focus on novel treatments for celiac disease and iron overload disorders, respectively.

In 2019, COI Pharmaceuticals acquired Calporta Therapeutics, a company developing selective small molecule agonists to TRPML1, with potential applications in treating lysosomal storage and neurodegenerative disorders. This acquisition highlights COI Pharmaceuticals' commitment to advancing innovative therapies in the biotechnology sector.